Polymer compositions and methods for their use

• US 20050208095A1
• Filed: 11/22/2004
• Published: 09/22/2005
• Est. Priority Date: 11/20/2003
• Status: Abandoned Application

• Current Assignee: Angiotech Pharmaceuticals Incorporated
• Original Assignee: Angiotech Pharmaceuticals Incorporated
• Inventors: Takacs-Cox, Aniko, Hunter, William L., Toleikis, Philip M., Avelar, Rui, Gravett, David M., Loss, Troy A. E., Liggins, Richard T., Maiti, Arpita
• Application Number:
  US10/996,354
• Publication Number:
  US 20050208095A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/432 Inhibitors, antagonists A61L2300/402 - A61L2300/43 take precedence
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

Claims

1. A method for implanting a medical device comprising:

(a) infiltrating a tissue of a host where the medical device is to be, or has been, implanted with i) an anti-fibrotic agent, ii) an anti-infective agent, iii) a polymer;

iv) a composition comprising an anti-fibrotic agent and a polymer, v) a composition comprising an anti-infective agent and a polymer, or vi) a composition comprising an anti-fibrotic agent, an anti-infective agent and a polymer, and (b) implanting the medical device into the host.

2. The method for implanting a medical device according to claim 1 comprising:

(a) infiltrating a tissue of a host where the medical device is to be, or has been, implanted with an anti-fibrotic agent, and (b) implanting the medical device into the host.

3. The method for implanting a medical device according to claim 1 comprising:

(a) infiltrating a tissue of a host where the medical device is to be, or has been, implanted with an anti-infective agent, and (b) implanting the medical device into the host.

4. The method for implanting a medical device according to claim 1 comprising:

(a) infiltrating a tissue of a host where the medical device is to be, or has been, implanted with a polymer; and

(b) implanting the medical device into the host.

5. The method for implanting a medical device according to claim 1 comprising:

(a) infiltrating a tissue of a host where the medical device is to be, or has been, implanted with a composition comprising an anti-fibrotic agent and a polymer, and (b) implanting the medical device into the host.

6. The method for implanting a medical device according to claim 1 comprising:

(a) infiltrating a tissue of a host where the medical device is to be, or has been, implanted with a composition comprising an anti-infective agent and a polymer, and (b) implanting the medical device into the host.

7. The method for implanting a medical device according to claim 1 comprising:

(a) infiltrating a tissue of a host where the medical device is to be, or has been, implanted with a composition comprising an anti-fibrotic agent, an anti-infective agent and a polymer, and (b) implanting the medical device into the host.

8. The method according to claim 1 wherein the device is an intravascular device.

9. The method according to claim 1 wherein the device is a gastrointestinal stent.

10. The method according to claim 1 wherein the device is a tracheal and bronchial stent.

11. The method according to claim 1 wherein the device is a genital urinary stent.

12. The method according to claim 1 wherein the device is an ear and nose stent.

13. The method according to claim 1 wherein the device is an ear ventilation device.

14. The method according to claim 1 wherein the device is an intraocular implant.

15. The method according to claim 1 wherein the device is a vascular graft.

16. The method according to claim 1 wherein the device comprises a film or a mesh.

17. The method according to claim 1 wherein the device is a glaucoma drainage device.

18. The method according to claim 1 wherein the device is a prosthetic heart valve or a component thereof.

19. The method according to claim 1 wherein the device is a penile implant.

20. The method according to claim 1 wherein the device is an endotracheal or tracheostomy tube.

21. The method according to claim 1 wherein the device is a peritoneal dialysis catheter.

22. The method according to claim 1 wherein the device is a central nervous system shunt or a pressure monitoring device.

23. The method according to claim 1 wherein the device is an inferior vena cava filter.

24. The method according to claim 1 wherein the device is a gastrointestinal device.

25. The method according to claim 1 wherein the device is a central venous catheter.

26. The method according to claim 1 wherein the device is a ventricular assist device.

27. The method according to claim 1 wherein the device is a spinal implant.

28. The method according to claim 1 wherein the device is an implantable electrical device.

29. The method according to claim 1 wherein the device is an implantable sensor.

30. The method according to claim 1 wherein the device is an implantable pump.

31. The method according to claim 1 wherein the device is a soft tissue implant.

32. The method of claim 1 wherein the anti-fibrotic agent inhibits cell regeneration.

33. The method of claim 1 wherein the anti-fibrotic agent inhibits angiogenesis.

34. The method of claim 1 wherein the anti-fibrotic agent inhibits fibroblast migration.

35. The method of claim 1 wherein the anti-fibrotic agent inhibits fibroblast proliferation.

36. The method of claim 1 wherein the anti-fibrotic agent inhibits deposition of extracellular matrix.

37. The method of claim 1 wherein the anti-fibrotic agent inhibits tissue remodeling.

40. The method of claim 1 wherein the anti-fibrotic agent is a chemokine receptor antagonist.

41. The method of claim 1 wherein the anti-fibrotic agent is a cell cycle inhibitor.

42. The method of claim 1 wherein the anti-fibrotic agent is a taxane.

43. The method of claim 1 wherein the anti-fibrotic agent is an anti-microtubule agent.

44. The method of claim 1 wherein the anti-fibrotic agent is paclitaxel.

45. The method of claim 1 wherein the anti-fibrotic agent is not paclitaxel.

46. The method of claim 1 wherein the anti-fibrotic agent is an analogue or derivative of paclitaxel.

47. The method of claim 1 wherein the anti-fibrotic agent is a vinca alkaloid.

48. The method of claim 1 wherein the anti-fibrotic agent is camptothecin or an analogue or derivative thereof.

49. The method of claim 1 wherein the anti-fibrotic agent is a podophyllotoxin.

50. The method of claim 1 wherein the anti-fibrotic agent is a podophyllotoxin, wherein the podophyllotoxin is etoposide or an analogue or derivative thereof.

51. The method of claim 1 wherein the anti-fibrotic agent is an anthracycline.

52. The method of claim 1 wherein the anti-fibrotic agent is an anthracycline, wherein the anthracycline is doxorubicin or an analogue or derivative thereof.

53. The method of claim 1 wherein the anti-fibrotic agent is an anthracycline, wherein the anthracycline is mitoxantrone or an analogue or derivative thereof.

54. The method of claim 1 wherein the anti-fibrotic agent is a platinum compound.

55. The method of claim 1 wherein the anti-fibrotic agent is a nitrosourea.

56. The method of claim 1 wherein the anti-fibrotic agent is a nitroimidazole.

57. The method of claim 1 wherein the anti-fibrotic agent is a folic acid antagonist.

58. The method of claim 1 wherein the anti-fibrotic agent is a cytidine analogue.

59. The method of claim 1 wherein the anti-fibrotic agent is a pyrimidine analogue.

60. The method of claim 1 wherein the anti-fibrotic agent is a fluoropyrimidine analogue.

61. The method of claim 1 wherein the anti-fibrotic agent is a purine analogue.

62. The method of claim 1 wherein the anti-fibrotic agent is a nitrogen mustard or an analogue or derivative thereof.

63. The method of claim 1 wherein the anti-fibrotic agent is a hydroxyurea.

64. The method of claim 1 wherein the anti-fibrotic agent is a mytomicin or an analogue or derivative thereof.

69. The method of claim 1 wherein the anti-fibrotic agent is a DNA alkylating agent.

70. The method of claim 1 wherein the anti-fibrotic agent is an anti-microtubule agent.

71. The method of claim 1 wherein the anti-fibrotic agent is a topoisomerase inhibitor.

72. The method of claim 1 wherein the anti-fibrotic agent is a DNA cleaving agent.

73. The method of claim 1 wherein the anti-fibrotic agent is an antimetabolite.

74. The method of claim 1 wherein the anti-fibrotic agent inhibits adenosine deaminase.

75. The method of claim 1 wherein the anti-fibrotic agent inhibits purine ring synthesis.

76. The method of claim 1 wherein the anti-fibrotic agent is a nucleotide interconversion inhibitor.

77. The method of claim 1 wherein the anti-fibrotic agent inhibits dihydrofolate reduction.

78. The method of claim 1 wherein the anti-fibrotic agent blocks thymidine monophosphate.

79. The method of claim 1 wherein the anti-fibrotic agent causes DNA damage.

80. The method of claim 1 wherein the anti-fibrotic agent is a DNA intercalation agent.

81. The method of claim 1 wherein the anti-fibrotic agent is a RNA synthesis inhibitor.

82. The method of claim 1 wherein the anti-fibrotic agent is a pyrimidine synthesis inhibitor.

83. The method of claim 1 wherein the anti-fibrotic agent inhibits ribonucleotide synthesis or finction.

84. The method of claim 1 wherein the anti-fibrotic agent inhibits thymidine monophosphate synthesis or function.

85. The method of claim 1 wherein the anti-fibrotic agent inhibits DNA synthesis.

86. The method of claim 1 wherein the anti-fibrotic agent causes DNA adduct formation.

87. The method of claim 1 wherein the anti-fibrotic agent inhibits protein synthesis.

88. The method of claim 1 wherein the anti-fibrotic agent inhibits microtubule function.

89. The method-of claim 1 wherein the anti-fibrotic agent is a cyclin dependent protein kinase inhibitor.

190. The method of claim 1 wherein the anti-infective agent is-an anthracycline.

191. The method of claim 1 wherein the anti-infective agent is-doxorubicin.

192. The method of claim 1 wherein the anti-infective agent is ismitoxantrone.

193. The method of claim 1 wherein the anti-infective agent is a fluoropyrimidine.

194. The method of claim 1 wherein the anti-infective agent is 5-fluorouracil (5-FU).

195. The method of claim 1 wherein the anti-infective agent is a folic acid antagonist.

196. The method of claim 1 wherein the anti-infective agent is methotrexate.

197. The method of claim 1 wherein the anti-infective agent is a podophylotoxin.

198. The method of claim 1 wherein the anti-infective agent is etoposide.

199. The method of claim 1 wherein the anti-infective agent is camptothecin.

200. The method of claim 1 wherein the anti-infective agent is a hydroxyurea.

201. The method of claim 1 wherein the anti-infective agent is a platinum complex.

202. The method of claim 1 wherein the anti-infective agent is cisplatin.

203. The method of claim 1 wherein the composition comprises an anti-thrombotic agent.

38-39. -39. (canceled)

65-68. -68. (canceled)

90-189. -189. (canceled)

204-8822. -8822. (canceled)